CLINICAL CORE (AND SMP)

《临床核心》是香港艺术发展局研究课题的主要来源。它的主要功能是为ADC相关研究项目和初步研究提供诊断良好的受试者和临床材料(例如血液、脑脊液等)。临床核心包括一个卫星多元文化计划(SMP)，该计划侧重于招募少数族裔。核心人群目前包括4900多例患者，包括阿尔茨海默病、其他痴呆症和轻度认知障碍患者，以及正常成人受试者。每年约有150至200个新科目加入核心课程。对人口进行纵向重新评估 并追踪到了尸检。所有数据都包括在由数据管理核心维护的中央数据库中。 在过去的五年中，临床核心已经超过了它的具体目标。从2005年1月1日至2009年3月20日，完成了732名新患者和1797次随访评估。自2005年10月以来，国家阿尔茨海默氏症协调中心(NACC)的统一数据集(UDS)措施已经在临床核心受试者中完成，导致UDS人数在所有ADC中最多，包括1,167名受试者，对其进行了708次随访。大多数核心受试者都参与了各种研究方案。自2005年以来，超过38项单独的联邦资助研究拨款利用了临床核心资源。CORE帮助支持参与多中心NIA-阿尔茨海默病合作研究(ADCS)的临床试验单位，自2005年以来，CORE参与了26项NIH ADCS和行业赞助的药理学试验。该核心还维护着一个脑脊液储存库和一个血清/DNA储存库，并与所有其他ADC核心密切互动。随着更新，我们建议继续关注临床核心在正常认知和轻度认知障碍之间的过渡。我们会继续跟进。 登记的病人。这样的努力将支持我们目前的NIH赠款组合、NIH NACC UDS主题捐款、ADCS研究和药物试验，以及其他合作和研究，并使我们能够有针对性地进行治疗性预防试验。

The Clinical Core serves as the central source of research subjects for the ADC. Its primary function is to provide ADC associated research projects and pilot studies with well-diagnosed subjects and with clinical materials (e.g., blood, CSF, etc.). The Clinical Core includes a Satellite Multicultural Program (SMP), which focuses on minority recruitment. The Core population currently includes more than 4,900 cases consisting of patients with AD, other dementias, and mild cognitive impairment, as well as normal adult subjects. About 150 to 200 new subjects have been added to the Core annually. The population is reassessed longitudinally and tracked to autopsy. All data are included in a central database maintained by the Data Management Core. During the past five years the Clinical Core has more than achieved its specific aims. From 1/1/2005 to 3/20/2009, 732 new patients and 1,797 follow-up evaluations were completed. Since October, 2005, National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS) measures have been completed in Clinical Core subjects resulting in the largest UDS population of any ADC, comprising 1,167 subjects on whom 708 follow-ups have been conducted. Most Core subjects participate in various research protocols. Since 2005, more than 38 separate federally funded research grants have utilized Clinical Core resources. The Core helps support a Clinical Trials Unit which participates in the multicenter NIA-Alzheimer's Disease Cooperative Study (ADCS) and since 2005, the Core has participated in 26 NIH ADCS and industry sponsored pharmacologic trials. The Core also maintains a CSF bank and a serum/DNA bank and has close interactions with all of the other ADC Cores. With renewal, we propose to continue to focus the Clinical Core on the transition between normal cognition and mild cognitive impairments. We will continue to follow-up enrolled patients. Such an effort will support our current portfolio of NIH grants, NIH NACC UDS subject contributions, ADCS studies and medication trials, as well as other collaborations and studies, and enable us to target therapeutic prevention trials.